Screening for ovarian cancer

Annals of the Academy of Medicine Singapore

Volumn 27, Issue 5, 1998, Pages 676-682

  MacDonald, N D ^a   Rosenthal, A N ^b   Jacobs, I J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

CA 125; Doppler; Ovarian neoplasm; Pelvic ultrasound; Tumour markers

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

AGED; BLOOD; CLINICAL TRIAL; ECHOGRAPHY; FEMALE; HUMAN; INCIDENCE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

AGED; CA-125 ANTIGEN; CLINICAL TRIALS; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; PHYSICAL EXAMINATION; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY;

EID: 0032150520     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Office of Population Censuses and Surveys (OPCS). Cancer statistics: registrations 1991. MB1 no.24. London: HMSO, 1997.
2. Boring C, Squires T, Tong T. Cancer statistics 1993. CA Cancer J Clin 1993; 43:7-26.
3. Nguyen N H, Averette H E, Hoskins W, Sevin B U, Penalver M, Steren A. National survey of ovarian carcinoma VI. Critical assessment of current International Federation of Obstetrics and Gynaecology staging system. Cancer 1993; 72:3007-11.
4. Plaxe S C, Deliglisch L, Dottino P R, Cohen C J. Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol 1990; 38:367-72.
5. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumours. Obstet Gynecol 1983; 83:181-6.
6. Puls L E, Powell D E, DePriest P D, Gallion H H, Hunter J E, Kryscio R J, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992; 47:53-7.
7. Wilson J, Jungner G. WHO principles and practice of screening for disease. WHO PA, 1968:66.7.
8. Zurawski V, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia; relevance for early detection of ovarian cancer. Int J Cancer 1988; 42:677-80.
9. Morgan R J, Copeland L, Gershenson D, Locker G, McIntosh D, Ozols R, et al. NCCN ovarian cancer practice guidelines. Oncology 1996; 10:293-310.
10. McFarlane C, Sturgis M C, Fetterman F S. Results of an experiment in the control of cancer of the female pelvic organs and report of a fifteen year research. Am J Obstet Gynecol 1955; 69:294-9.
11. Andolf E, Svalenius E, Astedt B. Ultrasonography for early detection of ovarian carcinoma. Br J Obstet Gynaecol 1986; 93:1286-9.
12. Jacobs I J, Oram D H. Potential screening tests for ovarian cancer. In: Sharp F, Mason W P, Leake R E, editors.Ovarian Cancer. London: Chapman and Hall Medical, 1990:197-205.
13. Bast R C Jr, Feeney M, Lazarus H, Nadler L M, Colvin R B, Knapp R C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68:1331-7.
14. Einhorn N, Sjovall K, Knapp R C, Hall P, Scully R E, Bast R C Jr, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992; 80:14-8.
15. Jacobs I, Davies A P, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography [see comments]. BM J 1993; 306:1030-4.
16. Skates S J, Xu F J, Yu Y H, Sjovall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumour markers. Cancer 1995; 76:2004-10.
17. Xu F G, Yu Y H, Li B Y. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells. Cancer Res 1991; 51:4012-9.
18. Campbell S, Bhan V, Royston P, Whitehead M I, Collins W P. Transabdominal ultrasound screening for ovarian cancer. BM J 1989; 299:1363-7.
19. Van Nagell J R, Gallion H D, Pavlik E J, DePriest P D. Ovarian cancer screening. Cancer 1995; 76:2086-91.
20. Kurjak A, Schulman H, Sosic A, Zalud I, Shalan H. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstet Gynecol 1992; 80:917-21.
21. Kurjak A, Shalan H, Kupesic, S, Kosuta D, Sosic A, Benic S, et al. An attempt to screen asymptomatic women for ovarian cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 1994; 13:295-301.
22. Yancik R, Gloeckler L, Yates J W. Ovarian cancer in the elderly: An analysis of surveillance, epidemiology and end results program data. Am J Obstet Gynecol 1986; 154:639
23. OPCS Cancer Statistics Registrations. Cases of diagnosed cancer registered in England and Wales. London: HM Stationery Office, 1992:26-31.
24. Jacobs I, Oram D. Screening for ovarian cancer. Biomed Pharmacother 1988; 42:589-96.
25. Bourne T H, Campbell S, Reynolds K, Hampson J, Bhatt L, Crayford T J, et al. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 1994; 52:379-85.
26. Bourne T H, Whitehead M I, Campbell S, Royston P, Bhan V, Collins W P. Ultrasound screening for familial ovarian cancer. Gynecol Oncol 1991; 43:92-7.
27. Beral V, Fraser P, Chilvers C. Does pregnancy protect against ovarian cancer? Lancet 1978; 1:1083-7.
28. Wolfe C D, Raju K S. The attitudes of women and feasibility of screening for ovarian and endometrial cancers in inner city practices. Eur J Obstet Gynecol Reprod Biol 1994; 56:117-20.
29. Guy R L, King E, Ayers A B. The role of transvaginal ultrasound in the assessment of the female pelvis. Clin Radiol 1988; 39:669-72.
30. Wardle F J, Collins W, Pernet A L, Whitehead M I, Bourne T H, Campbell S. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst 1993; 85:653-7.
31. Urban N, Drescher C, Etzioni R, Colby C. Use of a stochastic model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997; 18:251-70.
32. Piver M, Recio F. Issues in ovarian cancer screening. Contemp Oncol 1992; 2:26-36.
33. Kramer B S, Gohagan J, Prorok P C, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993; 71:589-93.